Latest Breaking News On - Pietro puglisi - Page 2 : comparemela.com

King s spin-out Heqet Therapeutics raises £6 6m

King s spin-out Heqet Therapeutics raises £6 6m
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomPietro puglisi clarisHansjoerg plaggemarsRichard trembathMauro giaccaPietro puglisiMarta antonucciHeikki lanckrietKing college londonHead of the school cardiovascular medicineCardiovascular labInternational centre for genetic engineeringHeqet therapeuticsClaris venturesInternational centre

Kither Biotech Raises €18 5 Million Series B and Appoints Dr Vincent Metzler as Chief Executive Officer | Comunicados | Edición USA

Kither Biotech Raises €18 5 Million Series B and Appoints Dr Vincent Metzler as Chief Executive Officer | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.

Vincent metzlerMarco kevin malisaniHeikki lanckrietLaura iris ferroEmilio hirschAlberto bardelliPietro puglisiAlessandra ghigoLeadership team of wilson therapeuticsClub degli investitoriUniversity of torinoJazz pharmaceuticalsUniversity of turinB future health fundMolecular biotechnology center university of turinKither biotech raises

Kither Biotech Raises €18 5 Million Series B and Appoints

Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer Proceeds to support the further development of.

Vincent metzlerMarco kevin malisaniHeikki lanckrietLaura iris ferroEmilio hirschAlberto bardelliPietro puglisiAlessandra ghigoUniversity of torinoJazz pharmaceuticalsUniversity of turinLeadership team of wilson therapeuticsClub degli investitoriB future health fundMolecular biotechnology center university of turinConsilium strategic communications

Kither Biotech Raises €18 5 Million Series B and Appoints Dr Vincent Metzler as Chief Executive Officer

Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace

Vincent metzlerMarco kevin malisaniHeikki lanckrietLaura iris ferroEmilio hirschAlberto bardelliPietro puglisiAlessandra ghigoUniversity of torinoJazz pharmaceuticalsUniversity of turinLeadership team of wilson therapeuticsClub degli investitoriB future health fundMolecular biotechnology center university of turinConsilium strategic communications

NeoPhore Announces £15 2m Financing to Advance DNA Mismatch Repair Pipeline

Share this article Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management CAMBRIDGE, England, March 9, 2021 /PRNewswire/ NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund. NeoPhore is focused on the discovery and development of novel first-in-class small molecule drugs targeting the DNA mismatch repair (MMR) pathway to treat cancer. NeoPhore will work closely with its scientific founder Dr Alberto Bardelli from the University of Turin where the original scientific discovery originated and Dr Luis Diaz (Memorial Sloan Kettering and SAB member) to exploit the concept that inhibition of MMR in tumours generates neoantigens that the patients own immune system can target with a powerful a

United kingdomEast lothianMatthew bakerHeikki lanckrietSloan ketteringRobert jamesMarianne bjordalPietro puglisiAlberto bardelliFujisawa pharmaHelsinn investment fundPrnewswire neophoreUniversity of turinElement capitalAstellas venture managementAstellas pharma inc